Protective antigenic sites identified in respiratory syncytial virus fusion protein reveals importance of p27 domain
Open Access
- 8 November 2021
- journal article
- research article
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (1) , e13847
Abstract
Respiratory syncytial virus (RSV) vaccines primarily focused on surface fusion (F) protein are under development. Therefore, to identify RSV‐F protective epitopes, we evaluated 14 antigenic sites recognized following primary human RSV infection. BALB/c mice were vaccinated with F peptides, F proteins, or RSV‐A2, followed by rA2‐Line19F challenge. F peptides generated binding antibodies with minimal in vitro neutralization titers. However, several F peptides (including Site II) reduced lung viral loads and lung pathology scores in animals, suggesting partial protection from RSV disease. Interestingly, animals vaccinated with peptides (aa 101–121 and 110–136) spanning the F‐p27 sequence, which is only present in unprocessed F0 protein, showed control of viral loads with significantly reduced pathology compared with mock‐vaccinated controls. Furthermore, we observed F‐p27 expression on the surface of RSV‐infected cells as well as lungs from RSV‐infected mice. The anti‐p27 antibodies demonstrated antibody‐dependent cellular cytotoxicity (ADCC) of RSV‐infected A549 cells. These findings suggest that p27‐mediated immune response may play a role in control of RSV disease in vivo, and F‐p27 should be considered for inclusion in an effective RSV vaccine.Keywords
Funding Information
- U.S. Food and Drug Administration (Intramural Funds)
This publication has 16 references indexed in Scilit:
- A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infantsScience Translational Medicine, 2017
- Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccinesVaccine, 2017
- Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment GlycoproteinsPLOS Pathogens, 2016
- A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanismNature Communications, 2015
- Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial VirusScience, 2013
- Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infectionVaccine, 2013
- Host Cell Entry of Respiratory Syncytial Virus Involves Macropinocytosis Followed by Proteolytic Activation of the F ProteinPLOS Pathogens, 2013
- Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial VirusThe Journal of Infectious Diseases, 1997
- Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia—RSV recombinants or RSVVaccine, 1992
- Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunizationVaccine, 1990